News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symphogen A/S Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association


6/10/2011 10:57:56 AM

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities and shows preliminary signs of clinical and biological activity by decreasing haemoglobin values.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES